Evicenter
P&T meetings

Atebrioz (zilurgisertib)

Fibrodysplasia ossificans progressiva

Also known as INCB000928
Regulatory submission
NDA submitted by May 2026
Last updated
96 sources

Product information and disease descriptionProduct descriptionProduct informationDosing and administration

Dosage

3 evidence topics · 1 source

Recommended dosage

“The recommended dosage of ATEBRIOZ is 100 mg orally once daily with or without food” (opens the prescribing information at this quote)

Pregnancy testing before treatment

“Verify that females of reproductive potential are not pregnant prior to initiating ATEBRIOZ” (opens the prescribing information at this quote)

Dosage modification with CYP3A4 inhibitors

“Reduce the ATEBRIOZ dosage to 50 mg orally once daily when used concomitantly with a strong CYP3A4 inhibitor. No change in ATEBRIOZ dosage is needed when used concomitantly with a mild or moderate CYP3A4 inhibitor” (opens the prescribing information at this quote)

Dosage modification for renal or hepatic impairment

No evidence found.